In a groundbreaking study set to reshape the landscape of HIV treatment, researchers have uncovered critical insights into the immune dynamics of people living with HIV (PLWH) who transition to a novel, long-acting injectable regimen consisting of cabotegravir and rilpivirine. This shift from traditional daily oral therapies to monthly or bimonthly injectable agents represents a major leap forward in HIV management, promising improved adherence and quality of life. However, the complexity of the immune system’s response to this therapeutic shift, particularly regarding monocyte-related immune activation, has remained obscure—until now.
Investigators led by Zingaropoli, Guardiani, Carraro, and their colleagues published a comprehensive study in Scientific Reports (2026), meticulously detailing the dynamic changes occurring in the immune profiles of PLWH undergoing this treatment switch. Their work elucidates how monocyte subsets, key players in innate immunity and inflammatory processes, adapt over time to injections of cabotegravir plus rilpivirine. Understanding these immunological recalibrations is indispensable, as chronic immune activation and inflammation in HIV are tightly linked to non-AIDS comorbidities and overall disease progression.
Monocytes, a subset of white blood cells pivotal to pathogen defense and tissue homeostasis, exist in heterogeneous populations characterized by distinct surface markers and functions. Classical monocytes (CD14++CD16−), intermediate monocytes (CD14++CD16+), and non-classical monocytes (CD14+CD16++) not only participate in clearing infections but also contribute to systemic inflammation when persistently activated. In untreated HIV infection, immune activation is rampant, but even in virally suppressed individuals on antiretroviral therapy, subtle monocyte activation persists, inciting concerns about residual inflammation’s role in cardiovascular disease, neurocognitive decline, and other morbidities.
This study’s longitudinal design followed a cohort of PLWH over a remarkable timeline, documenting immune parameters before and after switching to the injectable cabotegravir/rilpivirine regimen. Blood samples were analyzed using advanced flow cytometry to quantify monocyte subsets and their activation status by measuring markers such as CD163, CD64, and HLA-DR. Concurrently, soluble inflammatory biomarkers, including sCD14 and sCD163, were assessed, providing a multidimensional view of the immune environment.
Intriguingly, the researchers observed a transient surge in markers indicative of monocyte activation within the initial weeks following the switch to injectable therapy. This early phase was marked by elevated expression of activation markers on both classical and intermediate monocytes, suggesting an acute immunological response possibly triggered by pharmacokinetic changes or immune sensing of the injectable compounds. Importantly, this activation spike did not correlate with any clinical signs of inflammation or adverse events, pointing to a controlled and non-pathogenic process.
As treatment continued, a notable decline in monocyte activation markers was documented, with levels dipping below those observed during prior oral therapy. This downtrend implies that the injectable regimen may foster a more quiescent immune milieu over time, potentially attributable to sustained and consistent drug exposure minimizing viral replication and immune system perturbations. Such dampening of monocyte inflammatory signals could have broad implications for reducing HIV-related comorbidities driven by chronic inflammation.
The study also highlighted differential responses among monocyte subsets. Non-classical monocytes, often involved in vascular patrolling and repair, exhibited reduced activation states after prolonged exposure to cabotegravir plus rilpivirine. This suggests that the long-acting therapy might promote a restoration of monocyte functional balance, which is essential to mitigating endothelial dysfunction and atherogenesis frequently observed in PLWH.
Of particular interest was the interplay between monocyte activation and soluble markers of inflammation. The synchronization of decreased membrane-bound activation indicators with lower plasma levels of sCD14 and sCD163 reinforces the notion of an overarching systemic immune recalibration. These soluble markers have been robustly associated with poor clinical outcomes and neuroinflammation; thus, their reduction signifies a positive therapeutic impact beyond viral suppression.
Beyond the immunological parameters, the researchers posited mechanistic hypotheses addressing how cabotegravir and rilpivirine might modulate monocyte activity. These long-acting agents maintain stable plasma concentrations, circumventing peaks and troughs typical of daily oral regimens. Such pharmacokinetic steadiness possibly minimizes immune perturbations triggered by fluctuating drug levels, effectively blunting persistent immune activation. Furthermore, diminished cellular drug exposure variability could lower the antigen-presenting potential and inflammatory signaling mediated by infected reservoirs.
The methodological rigor of this investigation combined precise immunophenotyping, longitudinal clinical monitoring, and correlations with virological data to present a holistic picture of immune activation dynamics. Their approach underscores the nuanced balance between achieving viral suppression and containing immune system over-activation – a central challenge in optimizing HIV therapy.
These findings carry substantial clinical implications. By demonstrating that switching to long-acting injectable cabotegravir plus rilpivirine correlates with favorable modulation of monocyte-driven inflammation, this research paves the way for novel strategies aimed at reducing non-infectious HIV complications. This could ultimately translate into improved morbidity and mortality rates among PLWH with chronic immune activation refractory to standard treatments.
Importantly, this study also supports the expanding adoption of long-acting injectables as not only a convenience-enhancing option but as a potential immunomodulatory regimen that aligns with the goals of precision medicine in HIV care. Tailoring therapy to reduce residual immune activation may become a critical component in managing the aging population of PLWH, who face multimorbidity risks exacerbated by chronic inflammation.
Future research inspired by these results could explore the mechanistic underpinnings of monocyte activation suppression in greater molecular detail, possibly investigating the influence of cabotegravir-rilpivirine on monocyte transcriptomic profiles and epigenetic markers. Additionally, randomized controlled trials could extend these findings by evaluating clinical outcomes tied explicitly to inflammatory marker reductions, setting new benchmarks for therapeutic efficacy in HIV management.
Furthermore, the interplay between monocyte immune modulation and other cellular compartments, such as T cell exhaustion states or macrophage tissue-resident populations, offers fertile ground for inquiry. Integrative immunological studies combining systemic and tissue-level analyses may unravel complex immune network interactions influenced by long-acting therapies.
The revolutionary findings by Zingaropoli and colleagues represent a significant leap forward in understanding how novel HIV treatment modalities impact the intricate balance of host immunity. In revealing that switching to long-acting cabotegravir plus rilpivirine induces dynamic and ultimately favorable changes in monocyte-related immune activation, this study sets a new paradigm for both clinical practice and future scientific endeavors aimed at achieving functional HIV cure and improved patient well-being.
As the HIV care continuum evolves, embracing innovations that address not only viral replication but also immune dysregulation will be critical. This research highlights the promise that injectable long-acting antiretroviral therapies hold in moving the field toward that integrated, patient-centered vision. For millions living with HIV worldwide, these advances herald a new chapter of hope, empowerment, and sustained health beyond the virus itself.
Subject of Research: Immune activation dynamics in people living with HIV switching to long-acting injectable cabotegravir plus rilpivirine.
Article Title: Dynamic changes of monocytes-related immune activation in people with HIV switching to long-acting injectable cabotegravir plus rilpivirine.
Article References:
Zingaropoli, M.A., Guardiani, M., Carraro, A. et al. Dynamic changes of monocytes-related immune activation in people with HIV switching to long-acting injectable cabotegravir plus rilpivirine. Sci Rep (2026). https://doi.org/10.1038/s41598-026-44013-6
Image Credits: AI Generated
Tags: cabotegravir and rilpivirine treatmentchronic immune activation in HIVHIV treatment adherence improvementsimmune activation in HIV patientsinflammation and HIV comorbiditiesinjectable versus oral HIV therapiesinnate immunity in HIV treatmentlong-acting injectable HIV therapymonocyte immune shifts in HIVmonocyte role in HIV progressionmonocyte subsets in HIVnovel HIV therapeutic strategies
